Treatment Strategy & Options
At a Glance
Chronic Actinic Dermatitis (CAD) is treated in steps, starting with strict sun protection and topical creams. If symptoms persist, doctors may prescribe oral immunosuppressants, advanced biologics, or photohardening therapy to help the immune system safely build tolerance to sunlight.
Treatment for Chronic Actinic Dermatitis (CAD) is often approached in “steps.” Your care team will usually start with the most gentle options—focusing on protection and skin repair—before moving to stronger medications that adjust how your immune system functions [1][2].
Level 1: Foundations of Care
The first goal of treatment is to calm active inflammation and prevent new light from reaching your skin [1].
- Strict Photoprotection: This is the bedrock of CAD management. It includes broad-spectrum sunscreens, UV-protective clothing, and specialized window filters for your car and home [1][2].
- Topical Steroids & Calcineurin Inhibitors: Creams like hydrocortisone or clobetasol (steroids) and tacrolimus or pimecrolimus (non-steroid calcineurin inhibitors) are used to dampen the immune response directly in the skin [1].
- Emollients: Fragrance-free moisturizers help repair the skin barrier, which is often damaged and “leaky” in CAD patients [1].
Level 2: Systemic Immunosuppressants
If creams and avoidance aren’t enough to control the “fire” in your skin, doctors may suggest systemic medications—pills that work from the inside out to quiet the overactive immune system [1][3].
- Cyclosporine: Sometimes used as a rapid, short-term “rescue” therapy to bridge the gap while waiting for slower medications to work during a severe flare [1].
- Azathioprine: Traditionally considered a “gold standard” for CAD [1]. Before starting, your doctor must test your TPMT enzyme levels. This safety check ensures your body can safely process the drug, preventing severe bone marrow or liver toxicity [1].
- Methotrexate (MTX): Research suggests this may be just as effective as Azathioprine but with a potentially better safety profile and lower cost for some patients [4].
- Mycophenolate Mofetil (MMF): Often used if other systemics aren’t tolerated, MMF specifically targets the T-cells that drive the CAD reaction [1].
Important Safety Warning for Women: As CAD is increasingly diagnosed in younger women, it is critical to know that Methotrexate and Mycophenolate Mofetil (MMF) carry severe teratogenic risks, meaning they can cause severe birth defects [4][1]. Women of childbearing age must use strict, highly effective birth control while taking these medications.
Level 3: Advanced & Biologic Therapies
For patients with refractory CAD (disease that doesn’t respond to standard treatments), newer “targeted” therapies are showing significant promise [5][6].
- Dupilumab (Biologic): This injection targets the “Type 2” inflammation common in eczema. While it is excellent at clearing the itchy, red rash, it may be less effective at reducing your actual sensitivity to sunlight [7][5].
- JAK Inhibitors (Tofacitinib, Baricitinib, Abrocitinib): These pills block the signaling pathways (JAK/STAT) that immune cells use to communicate. They have shown “rapid and dramatic” clinical improvement in severe CAD cases in recent studies [6][8][9].
The Paradox: Photohardening
It may seem counterintuitive to treat a sun-allergic patient with light, but photohardening (also called photodesensitization) is a highly effective tool when performed under medical supervision [10][11].
By exposing the skin to very tiny, controlled doses of UV light (usually Narrowband UVB or UVA1), your immune system can slowly be “taught” to stop overreacting [12][13].
- How it works: It likely desensitizes the skin to the “new antigens” created by UV light [12].
- Safety: This must be done when the disease is stable—never during a severe flare—and often starts at a fraction of a normal person’s light dose to prevent a reaction [13][11]. Successful hardening can significantly improve your ability to spend time outdoors [10].
Summary of Medical Options
| Treatment Type | Examples | Primary Goal | Key Monitoring / Warnings |
|---|---|---|---|
| Topical | Steroids, Tacrolimus | Control local inflammation [1] | Skin thinning (steroids) |
| Systemic | Azathioprine | Quiet the immune system [1] | Requires TPMT enzyme testing |
| Systemic | Methotrexate, MMF | Quiet the immune system [4] | Liver/blood labs; Strict pregnancy prevention required |
| Biologic | Dupilumab | Target specific eczema pathways [7] | Monitoring for eye symptoms |
| JAK Inhibitor | Baricitinib, Tofacitinib | Stop immune cell signaling [6] | Blood work; Infection risk |
| Light Therapy | NB-UVB, UVA1 | Build UV tolerance (Hardening) [10] | Must be done closely with doctor |
Common questions in this guide
How do doctors treat chronic actinic dermatitis?
What is photohardening therapy for CAD?
Why do I need a TPMT test before taking azathioprine?
Are there new treatments for severe chronic actinic dermatitis?
Is it safe for women to take methotrexate or MMF for CAD?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which level of the treatment algorithm are we currently on, and what would be the trigger for moving to systemic or advanced therapy?
- 2.Before starting Azathioprine, will you test my TPMT enzyme levels to ensure it is safe for my liver and bone marrow?
- 3.Is my CAD 'refractory' (resistant to standard treatment), and would I be a candidate for newer JAK inhibitors or Dupilumab?
- 4.How do we safely transition from an active flare into a photohardening protocol without triggering a massive reaction?
- 5.What are the long-term side effects I should monitor if we decide to use Methotrexate or Mycophenolate Mofetil for several years?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Chronic actinic dermatitis in an old adult significantly improved by dupilumab.
Chen JC, Lian CH
Photodermatology, photoimmunology & photomedicine 2022; (38(2)):176-177 doi:10.1111/phpp.12731.
PMID: 34494309 - 2
Severe chronic actinic dermatitis treated successfully with Thalidomide.
Lahouel M, Ben Kahla M, Aounallah A, et al.
Photodermatology, photoimmunology & photomedicine 2020; (36(6)):493-495 doi:10.1111/phpp.12588.
PMID: 32654185 - 3
Immune Hemolysis: Diagnosis and Treatment Recommendations.
Barcellini W
Seminars in hematology 2015; (52(4)):304-12.
PMID: 26404442 - 4
Efficacy Of Methotrexate Versus Azathioprine In The Treatment Of Chronic Actinic Dermatitis: A Randomized Control Trial.
Paracha MM, Zahoor H, Khan AQ, et al.
Journal of Ayub Medical College, Abbottabad : JAMC 2022; (34(Suppl 1)(3)):S644-S648 doi:10.55519/JAMC-03-S1-9643.
PMID: 36414584 - 5
Dupilumab in chronic actinic dermatitis: a retrospective case series.
O'Reilly M, Paolino A, Pathmarajah P, et al.
The British journal of dermatology 2024; (191(2)):297-299 doi:10.1093/bjd/ljae180.
PMID: 38656979 - 6
Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis.
Vesely MD, Imaeda S, King BA
JAAD case reports 2017; (3(1)):4-6 doi:10.1016/j.jdcr.2016.09.008.
PMID: 28050588 - 7
Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series.
Ali K, Wu L, Lou H, et al.
Frontiers in medicine 2022; (9()):803692 doi:10.3389/fmed.2022.803692.
PMID: 35280879 - 8
Remission of chronic actinic dermatitis on baricitinib: A case report.
Maguire J, Gleeson D, Corso R, et al.
Skin health and disease 2023; (3(6)):e243 doi:10.1002/ski2.243.
PMID: 38047267 - 9
Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis.
Tang L, Zhong L, Liang L, et al.
Frontiers in medicine 2026; (13()):1742273 doi:10.3389/fmed.2026.1742273.
PMID: 41716804 - 10
Phototherapy in the Evaluation and Management of Photodermatoses.
Jiang AJ, Lim HW
Dermatologic clinics 2020; (38(1)):71-77 doi:10.1016/j.det.2019.08.007.
PMID: 31753194 - 11
Evaluation of narrow band ultraviolet B phototherapy in the treatment of chronic actinic dermatitis in Chinese patients.
Ma L, Zhang Q, Hu Y, Luo X
Dermatologic therapy 2017; (30(6)) doi:10.1111/dth.12528.
PMID: 29047198 - 12
Man of stone: A case of a chronic actinic dermatitis mimicking a cutis verticis gyrata.
Bourgaux M, Marcaillou M, Matei I, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(3)):e129-e130 doi:10.1111/jdv.16068.
PMID: 31715028 - 13
Ultraviolet A rush hardening for chronic actinic dermatitis: Pilot treatment outcomes.
Wang T, Gong Y, Rong W, et al.
The Journal of dermatology 2021; (48(3)):385-388 doi:10.1111/1346-8138.15667.
PMID: 33264455
This page explains Chronic Actinic Dermatitis (CAD) treatments for educational purposes only. Always consult your dermatologist to determine the safest and most effective treatment strategy for your specific skin condition.
Get notified when new evidence is published on Chronic actinic dermatitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.